Biopsy‐free screening for glioma
Abstract Circulating tumor DNA (ctDNA) is a promising diagnostic marker for many cancers and can be noninvasively assayed from blood. For diagnosing glioma, this approach has unfortunately proven to be of limited use since glioma contribute minimal ctDNA to the blood circulation. A more promising av...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2018-11-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.201809484 |
| _version_ | 1827015096810864640 |
|---|---|
| author | Alexandre Pellan Cheng Philip Burnham Iwijn De Vlaminck |
| author_facet | Alexandre Pellan Cheng Philip Burnham Iwijn De Vlaminck |
| author_sort | Alexandre Pellan Cheng |
| collection | DOAJ |
| description | Abstract Circulating tumor DNA (ctDNA) is a promising diagnostic marker for many cancers and can be noninvasively assayed from blood. For diagnosing glioma, this approach has unfortunately proven to be of limited use since glioma contribute minimal ctDNA to the blood circulation. A more promising avenue may therefore be to hunt for ctDNA in cerebrospinal fluid (CSF). The study by Mouliere et al in this issue of EMBO Molecular Medicine demonstrates that shallow whole‐genome sequencing of CSF‐cfDNA can be used to detect copy number alterations in glioma‐derived ctDNA, providing a low cost strategy to screen for glioma. |
| first_indexed | 2024-03-07T17:50:36Z |
| format | Article |
| id | doaj.art-2219ca548b834b2e8489be76740f0d18 |
| institution | Directory Open Access Journal |
| issn | 1757-4676 1757-4684 |
| language | English |
| last_indexed | 2025-02-18T14:17:39Z |
| publishDate | 2018-11-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj.art-2219ca548b834b2e8489be76740f0d182024-10-28T08:56:59ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842018-11-0110121310.15252/emmm.201809484Biopsy‐free screening for gliomaAlexandre Pellan Cheng0Philip Burnham1Iwijn De Vlaminck2Meinig School of Biomedical Engineering, Cornell UniversityMeinig School of Biomedical Engineering, Cornell UniversityMeinig School of Biomedical Engineering, Cornell UniversityAbstract Circulating tumor DNA (ctDNA) is a promising diagnostic marker for many cancers and can be noninvasively assayed from blood. For diagnosing glioma, this approach has unfortunately proven to be of limited use since glioma contribute minimal ctDNA to the blood circulation. A more promising avenue may therefore be to hunt for ctDNA in cerebrospinal fluid (CSF). The study by Mouliere et al in this issue of EMBO Molecular Medicine demonstrates that shallow whole‐genome sequencing of CSF‐cfDNA can be used to detect copy number alterations in glioma‐derived ctDNA, providing a low cost strategy to screen for glioma.https://doi.org/10.15252/emmm.201809484 |
| spellingShingle | Alexandre Pellan Cheng Philip Burnham Iwijn De Vlaminck Biopsy‐free screening for glioma EMBO Molecular Medicine |
| title | Biopsy‐free screening for glioma |
| title_full | Biopsy‐free screening for glioma |
| title_fullStr | Biopsy‐free screening for glioma |
| title_full_unstemmed | Biopsy‐free screening for glioma |
| title_short | Biopsy‐free screening for glioma |
| title_sort | biopsy free screening for glioma |
| url | https://doi.org/10.15252/emmm.201809484 |
| work_keys_str_mv | AT alexandrepellancheng biopsyfreescreeningforglioma AT philipburnham biopsyfreescreeningforglioma AT iwijndevlaminck biopsyfreescreeningforglioma |